Click to Translate to English Click to Translate to French  Click to Translate to Spanish  Click to Translate to German  Click to Translate to Italian  Click to Translate to Japanese  Click to Translate to Chinese Simplified  Click to Translate to Korean  Click to Translate to Arabic  Click to Translate to Russian  Click to Translate to Portuguese  Click to Translate to Myanmar (Burmese)

PANDEMIC ALERT LEVEL
123456
Forum Home Forum Home > Coronavirus Pandemic: Prepping Forums > Medical Intervention & Prevention
  New Posts New Posts RSS Feed - H5N1 treatment (New Research)
  FAQ FAQ  Forum Search   Events   Register Register  Login Login

Now tracking the new emerging South Africa Omicron Variant

H5N1 treatment (New Research)

 Post Reply Post Reply
Author
Message
Mahshadin View Drop Down
Admin Group
Admin Group
Avatar

Joined: January 26 2006
Location: United States
Status: Offline
Points: 3882
Post Options Post Options   Thanks (0) Thanks(0)   Quote Mahshadin Quote  Post ReplyReply Direct Link To This Post Topic: H5N1 treatment (New Research)
    Posted: February 13 2006 at 12:50pm
Aethlon Medical Announces Avian Flu Treatment Application
2/8/2006 

San Diego - Aethlon Medical, Inc. announced that it is expanding the applications of its Hemopurifier treatment technology to include the H5N1 strain of the Avian Flu Virus. The rapid progression of H5N1 infection allows only a brief treatment window with antiviral drugs. The Hemopurifier will target the direct capture of H5N1 and modulation of the immune response as a means to treat when drugs are ineffective or unavailable. In order to advance the H5N1 treatment application, Aethlon will manufacture and ship the treatment devices to established influenza researchers who will seek to establish the benefits of the Hemopurifier as a treatment against Avian Flu.

The application of the Hemopurifier to treat Avian Flu is based on evolving research that indicates a primary cause of death in H5N1 infection is the release of inflammatory cells and chemicals known as a "Cytokine Storm." As a result of cytokine storm, the immune system is hyper-activated to the extent that the normal immune response of clearing viruses, toxins, and infected cells becomes overshadowed by the destruction of healthy red blood cells. Antiviral drugs are not able to shut off a cytokine storm once it has been triggered. Thus, those individuals with robust immune systems are actually at greater risk than the immune compromised individuals who are most susceptible to regular seasonal flu strains. The hyper-activation of the immune system as a result of cytokine storm also fueled the Spanish Flu Pandemic of 1918. That pandemic is credited with killing between 20-50 million individuals in eighteen months.

The Hemopurifier offers the potential to provide the dual benefit of clearing H5N1 and modulating the overproduction of cytokines. The Hemopurifier is based on hemofiltration principals already indicated as a treatment for sepsis and shock caused by cytokine overproduction. In addition, the Hemopurifier design provides a mechanism to separate H5N1 from circulation so that it can be captured by immobilized affinity agents that bind to glycoproteins on the surface of the virus. Therefore, the Hemopurifier combines the potential to tame the immune system without destroying natural defenses, with the ability to reduce the body burden of infectious H5N1 virus.

SOURCE: Aethlon Medical

"In a time of universal deceit, telling the truth is a revolutionary act."   G Orwell
Back to Top
Mahshadin View Drop Down
Admin Group
Admin Group
Avatar

Joined: January 26 2006
Location: United States
Status: Offline
Points: 3882
Post Options Post Options   Thanks (0) Thanks(0)   Quote Mahshadin Quote  Post ReplyReply Direct Link To This Post Posted: February 13 2006 at 12:55pm

The Hemopurifier

Aethlon Medical has developed a patented extracorporeal device, known as the Hemopurifier™, to address the treatment of viral conditions that are either resistant or evolve resistance to drug and vaccine therapies. The Hemopurifier converges the established scientific principals of hollow-fiber dialysis and affinity chromatography with the discovery of affinity agents that selectively bind envelope viruses. The result is an affinity treatment cartridge that separates and captures circulating viruses, viral proteins, and toxins before the occurrence of cell and organ infection. The treatment goal is to reduce viral load burden without drug toxicity so that the patient's natural immunity can recover to wage an effective battle against viral infection. However, the mechanical nature of the Hemopurifier also allows it to be deployed in conjunction with other therapies including drugs and vaccines, if available. An additional benefit stems from treatment access, as the Hemopurifier has been designed for utilization in the global infrastructure of dialysis and continuous renal replacement machines already present in hospitals and clinics.

Scientific articles classify the Hemopurifier to be both an immunotherapy and fusion inhibitor treatment. The Food And Drug Administration (FDA) has indicated that the Hemopurifier will be treated as a Class III Medical Device in U.S. regulatory submissions. Pre-clinical human blood studies have documented the effectiveness of the Hemopurifier in capturing HIV (The AIDS Virus), HCV (Hepatitis-C), and Orthopox Viruses related to human Smallpox. The mechanism of capture has been shown to be via the polysaccharide chains that reside on the surface glycoproteins of envelope viruses. Since the polysaccharide portions of the viral glycoproteins are attached via normal host cell (functions not under control of the virus), they are highly invariant. Moreover, the high abundance of polysaccharides allows viruses to escape immune surveillance. Thus, while many viral proteins are highly variable in their primary structure, the polysaccharide chains are nearly invariant, allowing for the capture of all strains and clades of many viruses. In fact, lectin derived affinity agents immobilized within the Hemopurifier have been shown to inhibit the growth of all tested strains of HIV and can capture of inhibit the growth of other envelope viruses including SIV, FIV, HCV, Measles, Mumps, Influenza, Ebola, Marburg, and Orthopox viruses. Recent studies indicate that the Hemopurifier affinity agent is also able to capture Dengue hemorrhagic fever virus. In conclusion, the Hemopurifier has expansive therapeutic capabilities that address: global pandemics (HIV-AIDS); chronic infectious diseases (Hepatitis-C); naturally evolving pathogens; and pathogens weaponized for bioterrorism attacks against U.S. military and civilian populations.

"In a time of universal deceit, telling the truth is a revolutionary act."   G Orwell
Back to Top
Guests View Drop Down
Guest Group
Guest Group
Post Options Post Options   Thanks (0) Thanks(0)   Quote Guests Quote  Post ReplyReply Direct Link To This Post Posted: February 13 2006 at 4:27pm

Mahs, are you affiliated with the above?

Do you have any information other than what you have posted?

Do you have a patent number?

And last but most important..... We need you to post the URL's for the above if you snagged them from the net.

TIA,

SZ

Back to Top
Mahshadin View Drop Down
Admin Group
Admin Group
Avatar

Joined: January 26 2006
Location: United States
Status: Offline
Points: 3882
Post Options Post Options   Thanks (0) Thanks(0)   Quote Mahshadin Quote  Post ReplyReply Direct Link To This Post Posted: February 13 2006 at 8:30pm

I just ran across this doing searches on the subject. I am not affiliated with any company (I am a Computer Teacher at a Private College).

Anyway This looked like interesting medical info on a new viral treatment. I do not believe it is available but will be under study (Thats what I gathered).

Sorry bout the links they are below

Site

Article

"In a time of universal deceit, telling the truth is a revolutionary act."   G Orwell
Back to Top
Guests View Drop Down
Guest Group
Guest Group
Post Options Post Options   Thanks (0) Thanks(0)   Quote Guests Quote  Post ReplyReply Direct Link To This Post Posted: February 13 2006 at 8:57pm
Much appriciated Mahshadin!  We need to look at all things that may give us a leg up on this and it takes all of us to be on the lookout!
Back to Top
Mahshadin View Drop Down
Admin Group
Admin Group
Avatar

Joined: January 26 2006
Location: United States
Status: Offline
Points: 3882
Post Options Post Options   Thanks (0) Thanks(0)   Quote Mahshadin Quote  Post ReplyReply Direct Link To This Post Posted: February 14 2006 at 10:50am

Potential Bird Flu Treatment Studied In New Cutting-edge Research

The La Jolla Institute for Allergy & Immunology (LIAI) is making significant strides in the battle against the avian "bird" flu, with pre-clinical trials under way on a potential treatment conceived by one of its scientists. The Institute, a not-for-profit organization whose cutting-edge research focuses on infectious diseases and other immune system disorders, is also developing information for a "universal" flu vaccine, as well as researching a needle-free vaccine that would treat various influenza strains, including the avian flu.

The Institute, which launched an Emerging Infectious Disease and Biodefense Research Center in 2004, is conducting three major research initiatives to attack the influenza virus -- all of which may be applicable to the avian flu strain, known as the H5N1 virus. "We understand the devastating potential of an avian flu outbreak as well as the problems caused each year by the more conventional flu strains," said Mitchell Kronenberg, LIAI President and Scientific Director, noting that 200,000 Americans are hospitalized and 36,000 die each year from the flu. "Our researchers are working diligently to understand the cellular mechanisms that hold the key to preventing or treating influenza," he said. "We are particularly excited that our research shows promise against the avian flu, as that may be the most urgent health issue now facing the world."

A potential treatment for the avian flu involving human flu-fighting antibodies was conceived by LIAI scientist Hilde Cheroutre, Ph.D., and initiated through a collaborative effort of LIAI and Gemini Science, a biopharmaceutical research and development company and wholly-owned U.S. subsidiary of Kirin Brewery Co., Ltd. of Japan. Gemini moved forward in 2000 with laboratory testing on the antibodies, which have produced preliminary data showing positive results against numerous flu strains, including the H5N1 avian flu.

Cheroutre's concept focused on M2, a protein common to all influenza A viruses, including avian flu strains. Her insight was to suggest using a portion of the M2 protein to immunize Transchromosomic miceTM, which are mice genetically-engineered to produce human antibodies. The TC MouseTM Technology, developed by Kirin's Pharmaceutical Division, allowed researchers to obtain influenza M2-specific human antibodies.

In conducting the research, Gemini scientists used synthetically created pieces of the H5NI avian flu virus, along with a number of other synthesized virus pieces, to analyze the effectiveness of the human anti-M2 antibodies, which had been created from theTranschromosomic miceTM. "In laboratory (in vitro) testing, they found that the anti-M2 antibodies bound to several different influenza strains, including the avian flu virus (H5N1)," Cheroutre said. "This reactivity means that if used in vivo (in a living organism) the infected cells would be recognized by the antibody and destroyed by the immune system." The study also found that a relatively low dose of the antibodies was needed to fight the various flu strains.

While most of the work was done on virus pieces to avoid the risk of using actual viruses, Gemini also tested the M2 antibodies on mice infected with a potentially lethal influenza strain, with similarities to the avian flu virus. "They found that those mice which received the human M2 antibody were protected, while those mice that did not get the M2 antibody would die," Cheroutre said.

Based upon the lab and mice testing, Gemini Science is now initiating pre-clinical studies required for the commencement of human clinical testing of the anti-M2 antibody, said Shinichiro Kato, Ph.D., Gemini's Chief Scientific Officer. Gemini, which is testing the antibody both as a treatment and preventative measure against flu, has expedited the research due to the recent cases of avian flu. Gemini is currently in discussions with the Centers for Disease Control (CDC) about establishing a Cooperative Research and Development Agreement to jointly conduct further research. Gemini's findings were presented Saturday at the 45th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), which runs through Monday in Washington, D.C.

LIAI scientists are also engaged in other promising flu-related research, including work by scientist David Lo, M.D., Ph.D. Together with Neurome, Inc. in San Diego, Lo recently received a $3.9 million Bill and Melinda Gates Foundation Grand Challenges in Global Health grant to work on a mucosal flu vaccine that could be given orally or nasally. This needle-free vaccine delivery system would enable vaccines to be administered in any field setting without the need for complex equipment or specialized training. This would be particularly helpful for improving health in third world countries, which is the focus of the Gates grant. Along with a novel delivery system, if successful Lo's research would produce the world's first targeted mucosal flu vaccine, which would bind to specific receptors in mucosal surfaces such as airways and intestine. It is believed that such a vaccine would produce more rapid, potent and longer lasting flu protection than today's vaccines, because it would attack the virus in the mucosal linings where it enters the body. Lo said the vaccine would be designed to fight numerous flu strains, including the H5N1 avian flu.

LIAI's other major area of flu research involves studies that could lead to the development of a "universal" flu vaccine, meaning one that would protect against a broad cross section of flu viruses.

LIAI scientist Dr. Alessandro Sette, Ph.D., a renowned vaccine expert, is using powerful biomedical research tools to measure the immune response of people who have previously had the flu. His work involves comparing the various immune system reactions of test subjects against the genetic sequence of the vaccine virus.

"We are interested in seeing whether there are different components or pieces of the flu virus that are recognized by the immune system," he said, explaining this would mean the immune system had seen those pieces previously in earlier flu exposures. "Specifically, we're looking to see if there are proteins or genes that are common to many flu viruses that are targets of the immune response. If so, it may be possible to develop a vaccine with greater cross protection because it would recognize elements common to all flu viruses."

 

###

About LIAI
Founded in 1988, the La Jolla Institute for Allergy and Immunology is a nonprofit medical research center dedicated to increasing knowledge and improving human health through studies of the immune system. Scientists at the institute carry out research searching for cures for cancer, allergy and asthma, infectious diseases, and autoimmune diseases such as diabetes, inflammatory bowel disease and arthritis. LIAI's research staff includes more than 100 Ph.Ds.

article

"In a time of universal deceit, telling the truth is a revolutionary act."   G Orwell
Back to Top
Mahshadin View Drop Down
Admin Group
Admin Group
Avatar

Joined: January 26 2006
Location: United States
Status: Offline
Points: 3882
Post Options Post Options   Thanks (0) Thanks(0)   Quote Mahshadin Quote  Post ReplyReply Direct Link To This Post Posted: February 28 2006 at 8:37am
Israeli Product "Sambucol" Effective Against Avian Flu
18:14 Feb 28, '06 / 30 Shevat 5766

(IsraelNN.com) Retroscreen Virology, a medical research institute subsidiary of Queen Mary College, University of London, has announced that an Israeli medical preparation, Sambucol, reduced the quantity of cells infected with the avian flu virus by 99%, compared with a control group not treated with the virus. So reports Globes.

Another clinical trial on the product, developed by Razei Bar Industries, is currently underway at the Hadassah Medical Center in Ein Karem.

Sambucol was found to be effective at significantly neutralizing the infectivity of the virus in cell cultures. These results were presented during the International Conference on Bird Flu: “The First Pandemic of the 21st Century. A Central Role for Antivirals,” held at St. Bartholomew’s Hospital on January 19-20, 2006.

Article

"In a time of universal deceit, telling the truth is a revolutionary act."   G Orwell
Back to Top
Guests View Drop Down
Guest Group
Guest Group
Post Options Post Options   Thanks (0) Thanks(0)   Quote Guests Quote  Post ReplyReply Direct Link To This Post Posted: February 28 2006 at 8:48am

I know it's tempting, but resist grasping at straws.

Don't waste your vaulable time looking for the magic bullet. A Press Release does not a viable product make.

Focus on well-established H5 web sites and Government PanFlu information.

Stick to the basics.

Back to Top
 Post Reply Post Reply
  Share Topic   

Forum Jump Forum Permissions View Drop Down